口服大剂量米非司酮对子宫内膜癌细胞凋亡和端粒酶活性的影响

Effect of oral high dose mifepristone on apoptosis and telomerase activity of endometrial carcinoma

目的 研究口服大剂量米非司酮对子宫内膜癌细胞凋亡和端粒酶活性的影响 ,并探讨其作用机制。方法 12例未治疗的子宫内膜癌患者口服大剂量米非司酮 (10 0mg/d ,共 5天 )。第六天手术 ,用免疫组织化学法(LSAB法 )检测用药前后内膜癌组织Fas、FasL表达的变化。用半定量端粒重复序列扩增法 (semiquantitativetelomererepeatamplificationprotocol,TRAP)测定用药前后内膜癌组织端粒酶活性的改变。 结果 口服大剂量米非司酮后子宫内膜Fas表达明显升高 (P <0 0 1) ,FasL表达及端粒酶活性无明显改变 (P >0 0 5 )。结论 口服大剂量米非司酮可促进子宫内膜癌细胞凋亡 ,但对端粒酶活性无明显影响。

Objective To investigate the effect of oral high dose mifepristone on apoptosis and telomerase activity of endometrial carcinoma and to explore the possible mechanism associated with this effect.Methods Twelve untreated patients with endometrial carcinoma received high dose mifepristone(100mg/day for 5days) treatment.On the sixth day,these patients underwent operations.Immunohistochemistry assay(LSAB method) was applied to determine Fas and FasL expression changes of endometrial tissues between pre-and post-administration of high dose mifepristone.Using semiquantitative telomere repeat amplification protocol(TRAP)method,telomerase activity was measured.Results After administration of high dose mifepristone,expression of Fas was more intense than that of pre-treatment sections(P<0 01).There were no remarkable changes of FasL immunostaining and telomerase activity(P>0 05) after high dose mifepristone treatment.Conclusion High dose mifepristone can promote apoptosis of endometrial carcinoma but has no effect on telomerase activity.